Cipla reported a consolidated net profit of ₹789.05 crore for Q1 FY27, marking a sharp 39.2% decline from ₹1,297.62 crore posted in the same quarter of the previous financial year. However, on a sequential basis, net profit jumped 42% from ₹555 crore in Q4 FY26, demonstrating strong quarter-on-quarter recovery. The company's consolidated revenue from operations stood at ₹7,119.28 crore, up 9% quarter-on-quarter and 2% year-on-year from ₹6,957.47 crore in the year-ago period, though it was slightly below Bloomberg estimates of ₹7,131 crore. Total income, which includes other income, rose 1.6% to ₹7,330.18 crore from ₹7,216.03 crore in the corresponding quarter of the previous financial year. EBITDA declined to ₹1,192 crore from ₹1,778 crore a year ago, with EBITDA margins contracting sharply to 16.7% from 25.6% in the year-ago quarter, though sequential EBITDA margins improved to 16.74% from 14.6% in the previous quarter. Total expenses for the quarter came in at ₹6,248.25 crore, up 14.7% from ₹5,446.10 crore in the corresponding quarter of the previous financial year, with purchases of stock-in-trade rising 22.1% to ₹1,251.70 crore and employee benefit expenses increasing 14.1% to ₹1,497.41 crore. Cost of materials consumed declined 7.7% to ₹1,356.93 crore during the quarter.
On a sequential basis, net profit jumped 42% from ₹555 crore in Q4 FY26, while revenue from operations rose 9% from ₹6,541 crore in the fourth quarter. As per CNBC-TV18, total tax expense declined to ₹295 crore from ₹478 crore last year. Earnings per share stood at ₹9.77 compared to ₹16.07 in the year-ago period, though it improved from ₹6.87 on a sequential basis. Following the results announcement, Cipla shares were trading at ₹1,418.80 per equity share, up 1.84% at around 1:39 PM on Friday, with the stock gaining momentum as the market recognized the sequential improvement in operational performance. The stock gained 3.6% to touch the day's high at ₹1,444.80 per share in intraday trade, outperforming the Nifty 50 which was down 0.43% at 23,767.25. The stock has gained 1% in the past week but has fallen 1% over the month, with a year-to-date decline of 5%. The scrip has a total market capitalisation of ₹1.15 lakh crore as of July 24, 2026, according to NSE data. The market reaction reflects investor confidence in the company's recovery trajectory and strong domestic growth momentum, despite the significant year-on-year profit decline.
According to Business Standard, the India business posted revenue of ₹3,452 crore, up 12% year-on-year, marking its highest-ever quarterly revenue for the segment. The branded prescription business grew 15.4% during the quarter, with respiratory up 15%, diabetes 43%, cardiac 20%, and urology in double digits, according to IQVIA data for the quarter ended June 2026. The chronic therapy mix strengthened to 60.4%, demonstrating the company's focus on higher-value segments. Cipla's flagship inhalation brand, Foracort, crossed revenue of ₹1,000 crore, while two new brands were added to Cipla's ₹100 crore club, taking the tally to 33. The company continues to be the largest pharmaceutical company by volume in India, with more than 2 billion unit sales in the Indian Pharmaceutical Market (IPM) according to IQVIA MAT June 2026 data. Cipla said sales in India grew by a double-digit percentage in respiratory, anti-diabetes and cardiac chronic therapies, while the company is expanding in obesity treatments, including Yurpeak sold under a licensing agreement with Eli Lilly. Motilal Oswal highlighted that the India segment's YoY growth has been on an uptrend for the fourth consecutive quarter, driven by higher demand for chronic therapies, improving growth in acute therapies and strong execution in trade generics and consumer health.
According to Business Standard, Cipla's North America business reported quarterly revenue of $162 million, down 21% year-on-year, with the decline attributed to US supply disruptions related to tumor treatment lanreotide following a US Food and Drug Administration inspection at the facility of its sole lanreotide supplier. In dollar terms, the business reported quarterly revenue of $162 million, weighed down by the loss of exclusivity in lenalidomide and continued disruption in lanreotide supplies. The company maintained its full-year guidance for an EBITDA margin of 18.5-20% and expects a significant movement in North America revenue in the coming quarters as new product approvals come through, including three respiratory launches and one peptide opportunity, aiming for a $1 billion exit run rate for the region. Jefferies noted that the North America exit rate of US$250 million in Q4 is a tall ask, especially with a gradual ramp-up of recently launched gVentolin, with the brokerage seeing downside risk to the EBITDA margin guidance if key US launches are delayed. Choice Institutional Equities believes Cipla's earlier target of achieving US$1 billion in US revenue is likely to be deferred to FY28E, subject to the pace of product scale-up, with the brokerage expecting the US business to remain under pressure in FY27E.
Following the results, Motilal Oswal Financial Services maintained its "Neutral" rating on the stock with a target price of ₹1,420, raising its FY27 and FY28 earnings estimates by 4% and 2% respectively, driven by stronger domestic growth and continued momentum in the South Africa prescription business. However, Motilal Oswal cautioned that "FY27 is expected to be a second consecutive year of earnings decline as per its estimates," while potential product launches in 2HFY27 are expected to drive growth revival in FY28. JP Morgan analysts noted that while Cipla's Q1 revenues were broadly in line with expectations, its EBITDA margin missed estimates by 75 bps, though the company maintained full-year guidance of 18.5-20% despite the miss. Citi analysts stated that while Q1 earnings were largely in line, EBITDA and EBITDA margin came slightly below estimates mainly due to transient factors impacting gross levels. Nomura noted that Cipla missed its Q1 FY27 estimates, with EBITDA margin missing estimates by 156 bps, though the company retained its margin guidance. Jefferies maintained an underperform rating and raised its target price to ₹1,170 from ₹1,120, noting that higher costs drove a miss in the June quarter and downside risk to US guidance persists. Choice Institutional Equities reiterated its reduce rating and set a target price of ₹1,330, maintaining a cautious view amid persistent headwinds including delays in revenue contribution from key US product launches and ongoing impact of Revlimid.
Elara Capital maintained its 'Reduce' rating with a target price of ₹1,349, noting that Cipla reported poor Q1FY27, with revenue, EBITDA and profit after tax missing brokerage estimates by 2%, 11% and 16% respectively. The brokerage cut its FY27–FY29 core earnings estimates for Cipla by 2–8% and stated that Q1 EBITDA margin came in way below full-year guidance of 18.5-20% at 16.7%, making it difficult for the company to achieve full-year margin guidance. Nirmal Bang maintained its 'Buy' rating with a revised target price of ₹1,615 from earlier ₹1,883, noting that near-term earnings remain subdued, but the management reiterated its US$1bn North America exit run-rate, reinforcing confidence in a stronger H2FY27. The brokerage expects Cipla to deliver a 10% revenue CAGR over FY26-FY28E, underpinned by a stronger US pipeline, resilient domestic franchise, and healthy international execution. Nirmal Bang lowered its target price but retained its 'Buy' call and top pick view for Cipla on the heels of improving growth visibility, robust balance sheet, and attractive long-term earnings trajectory.
